More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$39.40B
EPS
1.52
P/E ratio
30.4
Price to sales
12.91
Dividend yield
1.369%
Beta
0.370273
Previous close
$68.53
Today's open
$67.92
Day's range
$67.62 - $68.77
52 week range
$37.31 - $70.37
show more
CEO
Pablo Legorreta
Employees
100
Headquarters
New York, NY
Exchange
Nasdaq Global Select
Shares outstanding
573605303
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Royalty Pharma plc (RPRX) Presents at UBS Global Biopharma Conference 2026 Transcript
Royalty Pharma plc (RPRX) Presents at UBS Global Biopharma Conference 2026 Transcript
Seeking Alpha • a day ago

Royalty Pharma to present at the UBS Global Biopharma Conference
NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the UBS Global Biopharma Conference on Tuesday, November 17, 2026 at 5:40 a.m. ET / 10:40 a.m. GMT.
GlobeNewsWire • Nov 12, 2026

Royalty Pharma: Stronger Royalty Growth Supports Further Upside
Royalty Pharma's Q3 royalty receipts increased 9% to $883 million, led by strong growth in Tremfya, Voranigo, and Evrysdi. Vertex now accounts for approximately 25% of royalty receipts, indicating that newer medicines are gradually reducing the portfolio's concentration. Management raised its 2026 guidance again, while new drug approvals, additional investments, and share buybacks support future growth.
Seeking Alpha • Nov 12, 2026

3 Biotech Stocks That Actually Pay Dividends and Keep Raising Them
Biotech usually torches cash and dilutes shareholders to fund the next trial. Three drugmakers flip that script, and the one with the smallest yield may be hiding the sturdiest payout of all.
24/7 Wall Street • Nov 10, 2026

Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer Drug
Revolution Medicines' daraxonrasib has received FDA approval. Royalty Pharma estimates that the drug could produce peak revenues of $11 billion.
The Motley Fool • Nov 8, 2026

Royalty Pharma (RPRX) Upgraded to Buy: What Does It Mean for the Stock?
Royalty Pharma (RPRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks Investment Research • Nov 6, 2026

Royalty Pharma Q3 Earnings Call Highlights
Royalty Pharma NASDAQ: RPRX reported third-quarter portfolio receipts of $890 million, up 9% from a year earlier, as growth in its diversified royalty portfolio offset declines in certain products. The company raised its full-year 2026 outlook for the third consecutive quarter, citing continued momentum in recurring royalty receipts.
MarketBeat • Nov 4, 2026

Royalty Pharma plc (RPRX) Q3 2026 Earnings Call Transcript
Royalty Pharma plc (RPRX) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 4, 2026

Royalty Pharma reports third quarter 2026 results
Portfolio Receipts growth of 9% to $890 million; Royalty Receipts growth of 9% Net cash provided by operating activities of $686 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,500 million to $3,550 million NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts. “Royalty Pharma delivered excellent third quarter 2026 results and we again raised our financial guidance,” said Pablo Legorreta, Royalty Pharma's Chief Executive Officer and Chairman of the Board.
GlobeNewsWire • Nov 4, 2026

Royalty Pharma (RPRX) Q3 Earnings and Revenues Surpass Estimates
Royalty Pharma (RPRX) came out with quarterly earnings of $1.21 per share, beating the Zacks Consensus Estimate of $1.18 per share. This compares to earnings of $1.17 per share a year ago.
Zacks Investment Research • Nov 4, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Royalty Pharma plc commission-free¹. Build wealth for the long term using automated trading and transfers.